Welcome
Make the most of breakthrough treatments for early and advanced breast cancer.
- Become an expert in navigating the treatment landscape for early and advanced breast cancer
- Apply your knowledge to stratify and assess patients on the basis of their risk of recurrence
- Identify patients with early and advanced breast cancer who may benefit from CDK4/6 inhibitor treatment
Dr Gregory Vidal, a medical oncologist at the West Cancer Centre and Research Institute and University of Tennessee, USA, explains why it is important for clinicians to keep on top of the current and future data for CDK4/6 inhibitors in breast cancer.
Implementing guideline recommendations for CDK4/6 inhibition in early breast cancer
Join the expert faculty in this roundtable
Breast cancer
An overview of breast cancer stages and CDK4/6 inhibitors
CDK4/6 inhibitor trials in breast cancer
Clinical trial data on CDK4/6 inhibitors in early and advanced breast cancer
CDK4/6 inhibitor selection
Selecting CDK4/6 inhibitors in advanced breast cancer
Recurrence in early breast cancer
Identifying risk of recurrence in early breast cancer
EACCME® accredited module in Early breast cancer and risk stratification
Learn about early breast cancer risk stratification and management
CDK4/6 inhibitor selection eLearning
Follow three patient case studies in this interactive module
Publication digest
Concise infographic summaries on early breast cancer stratification
SABCS, ASCO and ESMO - CDK4/6 inhibitors in breast cancer
Congress highlights from SABCS 2022, ASCO and ESMO
Our Experts
Throughout this Learning Zone, you will hear from some of our CDK4/6 inhibitor and breast cancer experts, including:
- Dr Gregory Vidal is a haematologist/medical oncologist and clinical investigator at the West Cancer Centre and Research Institute and University of Tennessee, USA
- Dr Laura Spring is a medical oncologist and clinical translational investigator at the Massachusetts General Hospital Cancer Centre and Harvard Medical School, USA
- Dr Stephen Johnston is a Professor of Breast Cancer Medicine and Consultant Medical Oncologist, the Royal Marsden NHS Foundation Trust and the Institute of Cancer Research, UK
- Professor Nadia Harbeck is Head of the Breast Cancer Centre at LMU University in Munich, Germany
of interest
are looking at
saved
next event
This activity is supported by an educational grant from Eli Lilly and Company, this content has been developed by IMR International (Australia) independently of the sponsor Eli Lilly, who have had no editorial input into the content. IMR International (Australia) received unrestricted educational funding from the sponsor to help provide healthcare professional members with access to the highest quality medical and scientific information, education and associated relevant content.